Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05657873 · ClinicalTrials.gov registry record · Phase 2
A Study of Targeted Radiation Therapy in People With Non-Small Cell Lung Cancer (NSCLC)
A Phase 2 study of Non-Small Cell Lung Cancer and NSCLC, sponsored by Memorial Sloan Kettering Cancer Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 68
- Enrollment target
- 9
- Study locations
NCT05657873 is a Phase 2 study of Non-Small Cell Lung Cancer and NSCLC that is actively recruiting participants, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 68 participants, below the 659-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (90% lower). The trial reports 9 study locations across 4 states.
The verdict
NCT05657873, a Phase 2 study of Non-Small Cell Lung Cancer and NSCLC, is actively recruiting participants, sponsored by Memorial Sloan Kettering Cancer Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 68 participants
- Enrollment target
- 9
- Study locations
Study Summary
The purpose of this study is to see whether adding liver stereotactic ablative radiotherapy/L-SABR to standard drug therapy is better than standard drug therapy alone for people with metastatic non-small cell lung cancer/NSCLC.
Conditions Studied
Interventions
- DRUG Platinum based chemotherapy
- RADIATION L-SABR
- BIOLOGICAL Anti-PD-(L)1 based immunotherapy
Study Locations (9)
New York
- Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities) - Commack
- Memorial Sloan Kettering Westchester (All Protocol Activities) - Harrison
- Memorial Sloan Kettering Cancer Center (All Protocol Activities) - New York
- Memorial Sloan Kettering Nassau (All protocol activities) - Rockville Centre
New Jersey
- Memorial Sloan Kettering at Basking Ridge (All Protocol Activities) - Basking Ridge
- Memorial Sloan Kettering Monmouth (All Protocol Activities) - Middletown
- Memorial Sloan Kettering Bergen (All protocol activities) - Montvale
Florida
- BAPTIST ALLIANCE - MCI (Data Collection Only) - Miami
Pennsylvania
- Lehigh Valley Health Network (Data Collection Only) - Allentown
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 68 participants |
| Start Date | 2022-12-09 |
| Est. Completion | 2026-12-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05657873
The ClinicalTrials.gov registry entry for NCT05657873 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 68 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 659-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (90% lower). The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 3 interventions - of which Platinum based chemotherapy is the first listed.
NCT05657873 reports 9 study locations spanning 4 distinct geographic areas - top geographies include New York, New Jersey, Florida.
Frequently Asked Questions
What is clinical trial NCT05657873 about?
NCT05657873 is a clinical study titled "A Study of Targeted Radiation Therapy in People With Non-Small Cell Lung Cancer (NSCLC)". The purpose of this study is to see whether adding liver stereotactic ablative radiotherapy/L-SABR to standard drug therapy is better than standard drug therapy alone for people with metastatic non-small cell lung cancer/NSCLC.
What is the current status of trial NCT05657873?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 68 participants. The study started on 2022-12-09. Estimated completion is 2026-12-09.
What conditions does trial NCT05657873 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer, NSCLC, Non Small Cell Lung Cancer Metastatic, NSCLC Stage IV, Non-small Cell Carcinoma.
What interventions are being tested in trial NCT05657873?
The interventions under investigation include: Platinum based chemotherapy (DRUG), L-SABR (RADIATION), Anti-PD-(L)1 based immunotherapy (BIOLOGICAL).
Who is sponsoring clinical trial NCT05657873?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05657873 being conducted?
This trial has 9 study locations across Florida, New Jersey, New York, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
RECRUITING · Phase 2
-
Reduced CT + Anti-PD-1 as First Line Tx in Vulnerable Older Adults w/Adv <50% PD-L1 Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
RECRUITING · Phase 2
-
A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Zelenectide Pevedotin in NECTIN4 Amplified Advanced or Metastatic Non-small Cell Lung Cancer
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.